Zika virus (ZIKV), a single-stranded RNA virus of the Flaviviridae family, is an arbovirus (viruses transmitted by arthropods) transmitted to humans and non-human primates through the bites of infected female Aedes sp. mosquitoes. Although first isolated in 1947, it only recently emerged as a global threat, present in several countries resulting in a pandemic scenario. ZIKV infections may have severe outcomes, such as neurological impairment, and with the intrinsic ability of inducing microcephaly in fetuses of infected pregnant women, the virus has become a major public health problem. This review discusses some advances in diagnosis; vaccine development and the problems associated with their administration; the importance of the cross-reactivity with other flaviviruses in protecting or worsening the disease; the implications of the recent outbreak caused by the virus in the world; and future prospects for the complete understanding of this disease.
Introduction
Zika virus (ZIKV) is a mosquito-borne pathogen that belongs to the Flaviviridae family. First isolated from a sentinel Rhesus monkey in 1947 at Ziika Forest, Uganda, 1 it was not until 1954 that ZIKV was associated with a febrile disease in humans, since then named Zika. 2 ZIKV is primarily transmitted by mosquitoes from the genus Aedes sp., but other forms of transmission have recently been reported, such as sexual, 3 congenital 4 and by blood transfusion. 5, 6 ZIKV, like all mosquito-borne flaviviruses, is a small enveloped virus with an icosahedral capsid structure and a positive-sense RNA genome of approximately 12 kb. The genomic organization consists of three structural genes [Capsid (C), pre-Membrane/Membrane (prM/M) and Envelope (E)] and seven non-structural genes (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5) organized in a single open-reading frame that is translated into one single polyprotein and cleaved by both host and viral proteases. 7 Phylogenetic analysis based on nucleotide and amino acid composition shows that the ZIKV genome is separated in two major distinct lineages (African and Asian). 8 It is assumed that both lineages can cause the same disease; most ZIKV infections are asymptomatic 9, 10 and, when symptomatic, cause a mild febrile illness characterized by a headache, myalgia, fever, rash and non-purulent conjunctivitis. 11 There is no treatment for Zika, other than symptomatic relief, since the viraemia lasts only a few days after disease onset. Also, no commercial vaccine is available, although some candidates using distinct approaches, such as inactivated particles, 12 attenuated virus 13 and DNA constructs, 14 are being evaluated and could be used as a preventive tool for the disease.
Not much attention was given to ZIKV infection until recently, when an association with neurological involvement was observed. Two distinct neurological disorders have been associated with ZIKV infection: microcephaly in newborns whose mothers had Zika during their pregnancy, first detected in Brazil since the beginning of a ZIKV outbreak in 2015, 15 and Guillain-Barr e syndrome, whose incidence has increased in regions undergoing outbreaks of ZIKV infection. A lot of information about this emergent disease has been acquired in a short period of time, but many important key points still need a better understanding. New studies must address these points to improve our knowledge about this disease and, when possible, enable implementation of strategies to achieve better control of this infection and avoid its complications.
Epidemiology
In 1947, during a yellow fever virus study in the Ziika Forest, Uganda, a Rhesus monkey (Rhesus 766) presented with high fever (39Á7-40°) and its serum was injected into mouse brains, where Zika virus was first isolated (MR766 strain). Several months later, the virus was isolated from Aedes africanus mosquitoes collected in the same forest. 1 Already at that point, a close relationship between this virus and the Aedes mosquitoes was established, but due to its localized distribution and low impact on human health, very few studies on ZIKV had been done until recently.
The first cases of human infections were reported in 1954 in Nigeria during an epidemic of jaundice, which was initially suspected of being a yellow fever outbreak. ZIKV was isolated from one patient through serum inoculation into the mouse brain, and two other individuals had increasing high levels of neutralizing antibodies against this virus. Probably because of the high incidence of asymptomatic illness, the very low burden of the disease in the African continent (where ZIKV is endemic and people are infected early in life), and the limited ability to detect this virus, very few studies regarding ZIKV infections were available between its isolation and the first large epidemic, in 2007 (Yap Island, Micronesia). During the investigation of this epidemic, ZIKV RNA was identified in acute-phase patients and a high prevalence of IgM antibodies against ZIKV was found in the local population, leading to the conclusion that the majority of cases were asymptomatic. 17, 18 The evidence for the worldwide importance of ZIKV infections began in 2013 when an outbreak of the infection was reported in French Polynesia, and from there spread to adjacent islands, including New Caledonia during 2014, resulting in an estimated number of approximately 30 000 suspected cases between 2013 and 2014. 19 However, it was not until a huge outbreak occurred in Brazil that infections caused by ZIKV caught world attention, especially because of the increase in microcephaly incidence that was attributed to this virus. In Brazil, ZIKV infection was confirmed in May 2015, and according to phylogenetic analysis, the virus was introduced in the state of Pernambuco by travellers either from French Polynesia or Southeast Asia during the 2013 Confederations Cup. 20 Since its detection, nearly 270 000 suspected cases had been reported in Brazil by April 2017, and the virus has spread from the northeast region to all states of the country, although only three deaths have been confirmed by laboratory diagnosis. 21 A highly susceptible population, the warm climate and the large infestation of Aedes mosquitoes may have contributed to the fast dissemination of the disease in Brazil and other countries located in the tropical and subtropical regions of the world. The most recent Bulletin of the World Health Organization states that 84 countries and territories have reported evidence for mosquito-borne transmission of ZIKV (Fig. 1) since the Micronesia outbreak, with the majority of them reporting the disease after the first Brazilian cases. 22 The reasons for the increased capacity of transmission of ZIKV to almost all regions of the world must be studied, taking into consideration not only the worldwide susceptibility to this virus but also other parameters, such as genomic mutations that might have increased the viral fitness of the Polynesian strain. 23 Another important aspect of this disease that stands out in comparison to other flaviviruses is the ability of sexual transmission -13 countries have reported personto-person transmission. Are virus concentrations in the semen or vaginal secretions similar to those found in blood? Are the strains excreted in the semen or vaginal secretions the same circulating in the blood? Do they have different cellular tropism from the circulating strains? How frequent and what is the importance of the extended viraemia (and excretion in semen) in infected people? These are simple questions that must be investigated in order to understand whether this is an intrinsic characteristic of this virus or whether other factors are involved in this way of transmission. It is of paramount importance to clarify these questions because they are extremely important to couples' personal decisions on whether to conceive naturally or by in vitro fertilization. This decision is harder to take in countries where other flavivirus infections are prevalent because of the high cross-reactivity observed between antibodies induced by ZIKV and dengue virus infections. In these countries, sole detection of ZIKV IgM antibodies, as recommended by the Centers for Disease Control and Prevention (CDC), 9 may not be enough to prevent sexual transmission and couples should be initially tested for the presence of IgM antibodies and, if positive, should be tested using RT-PCR for the presence of ZIKV RNA in their semen and vaginal secretions. An important issue raised in the CDC guidelines to prevent sexual transmission of ZIKV is the counselling of sexual partners on the risks of sexual transmission and the possible transmission of ZIKV to their fetuses. Furthermore, it is important to define the rate of perinatal transmission as this form of transmission has not been studied in depth and the central nervous system involvement in these cases may be subtle. The importance of ZIKV infections to central nervous system development at specific gestational ages will only be defined in the years to come; currently, we do not know what is the degree of the damage to the central nervous system in each period of fetus/child development.
Finally, another important aspect of the epidemiology of ZIKV infections is the possibility of blood-borne transmission. Although Musso et al. reported, in 2014, potential ZIKV transmission by blood transfusion, 5 the first evidence for a ZIKV transmission by a blood component (platelet concentrate) was reported in Brazil 6 and resulted in the first complete genomic sequence of a Brazilian ZIKV. 24 The risk of blood-borne transmission may be associated with the magnitude of the epidemic, and reports on the prevalence of ZIKV RNA detection by RT-PCR in blood donors that were asymptomatic indicated that around 3% of them were infected by the virus. 5 We performed a similar study to that of Musso et al., in a region of Brazil with a low incidence of Zika, and the prevalence rate of ZIKV RNA detected in blood of asymptomatic blood donors was only 0Á16% (data not shown). Hence, as the ZIKV viraemia is very short and the risk for blood-borne transmission depends on the disease incidence, testing blood will only be necessary for high-incidence areas.
In 2017, the number of ZIKV reported cases dropped dramatically in Brazil and other American countries, and it is difficult to predict the intensity of future outbreaks. A number of factors may have influenced this low incidence of ZIKV infections in 2017, such as the large number of infected people (most of them asymptomatic) that have acquired a protective immunity against new ZIKV infections. Also, due to the worldwide importance of this outbreak, with several associated complications, wellcontrolled vector management policies may have been introduced in several countries and contributed to a decrease in reported cases. However, this fact may not be interpreted as a final step in controlling this disease because a large drop in government investments for ZIKV-related research may follow, a fact that can already be observed as the epidemic is no longer considered an international medical emergency by the World Health Organization.
Clinical manifestations and diagnosis
Zika virus infection was first reported as a mild denguelike disease, with clinical manifestations that are very similar to other flavivirus infections. 17 Viraemia is short-lived (an average of 4-5 days) and symptoms can include low fever, myalgia, a maculopapular rash, arthralgia, headache and a non-purulent conjunctivitis. 25 Previous outbreaks have reported that ZIKV infection had a high incidence (nearly 80%) of asymptomatic cases, 17 but no data are available for the outbreaks occurring in the Americas. Anecdotal reports indicate that the percentage of symptomatic cases in Brazil is higher than previously reported in Micronesia and French Polynesia, because if the proportion of asymptomatic cases was similar to that in the French Polynesian epidemics, the Brazilian outbreak was of outrageous proportions. Defining the percentage of asymptomatic cases through serological surveys in areas where other flaviviruses circulate is very difficult because of the high antibody cross-reactivity directed to these viruses. In these areas, ELISA-based serological diagnosis is not specific, particularly due to the intense reactivity with dengue virus, a flavivirus that is endemic in most of the tropical and subtropical world. The lack of specific serological methods to characterize the disease makes it difficult to precisely diagnose infected individuals, especially during the convalescent phase of the disease. A key objective regarding the correct diagnosis of ZIKV infections is the development of a diagnostic test that is able to differentiate ZIKV infections from other flavivirus infections and can be used on a large-scale, a feature that is not feasible with neutralizing antibody protocols. On the other hand, the specific diagnosis in the acute phase of the disease is easily achieved by molecular detection of ZIKV RNA in serum during the first days of symptoms (up to 4 days from the disease onset) or in urine (up to 14 days from disease onset), but this diagnostic approach is not always readily available in developing countries, such as Brazil. For these reasons, it is believed that the real number of cases of Zika is higher than officially reported, underestimating the epidemic scenario in Brazil. 26 As the symptoms observed with other arbovirus infections, such as chikungunya and dengue virus infections, are very much alike, for epidemiological standpoints and adequate management of clinical cases the diagnostic and correct identification of these diseases are extremely important in places where these viruses co-circulate. The CDC recommends molecular testing in the first few days after the onset of the disease and although the sensitivity of the available kits can vary, some diagnostic approaches (even a triplex-virus detection by quantitative RT-PCR, for dengue, chikungunya and Zika viruses) are available to distinguish these infections. If the results are negative or the disease is in a convalescent phase, MAC-ELISA should be performed to detect ZIKV IgM antibodies. This test, if positive, will show a presumptive ZIKV infection that needs to be confirmed by plaque reduction neutralization test. 27 The problem is that plaque reduction neutralization tests are time-consuming and need a laboratory infrastructure that is not always present in all locations. Finally, another approach to reach a Zika diagnosis, if the disease is of less than 1 week duration, is to perform an RT-PCR on urine, as ZIKV excretion in the urine is longer than for the other viruses.
Probably as a result of the large number of Zika cases reported in 2015 and 2016, some severe manifestations of the disease, that were not evident in previous outbreaks, have now been associated with ZIKV infections. Several ocular impairments, 28, 29 birth defects such as arthrogryposis, 30 microcephaly 15, 31 and other congenital disease manifestations, 32 as well as the Guillain-Barr e syndrome 33 are now linked to ZIKV infection. More recently, reports of severe thrombocytopenia have been described in patients infected with ZIKV. 34 Although these new clinical presentations are commonly associated with ZIKV infections, research is needed to unveil the pathophysiology behind each one. At least for microcephaly and ocular involvement, the presence of the virus seems to be a necessary event, 31 but for some presentations, an immune-mediated disease must be ruled out.
The association of microcephaly with ZIKV infection was suspected due to the increased incidence of microcephalic babies in Brazil in September 2015, following the Zika outbreak in the same year. 35 Confirmation of vertical transmission of ZIKV came in early 2016, with the detection of the virus in the brain of an infected fetus, in which the mother was probably infected in Brazil during the first trimester of pregnancy. 31 Retrospective studies have also associated microcephaly with ZIKV infection in other outbreaks around the world. Although a low incidence of microcephaly was reported in Yap Island (2007 outbreak) and French Polynesia (2013/14 outbreak), the risk of microcephaly seems to be higher when the infection occurs during the first trimester of pregnancy. 36, 37 In Brazil, a correlation between microcephaly and infection with ZIKV during the first trimester of pregnancy was also stronger, but reports of infection during all months of pregnancy is reported. 38 There is still a lack of information on the real impact of ZIKV infections on pregnancies, such as other outcomes resulting from ZIKV infections; the real risk for the development of microcephaly due to ZIKV infection during pregnancy; the real incidence of congenital Zika disease in all parts of the world; if developmental delay or other neurological sequelae will occur in all children born from ZIKV-infected mothers; what is the outcome of fetuses infected during different periods of the pregnancy; and what are the external and intrinsic factors associated with fetus infection.
Another important issue concerning the long-term follow up of ZIKV-infected newborns is the need for a frequent evaluation of these children because several problems can result from microcephaly, such as cognitive developmental delay, mobility problems, vision and/or hearing defects. 39, 40 In addition to microcephaly, newborns whose mothers were infected with ZIKV during their pregnancy and were born without microcephaly also need to be followed for a long time because other birth defects may be evident late in the course of the child's development. This is going to be a huge economic burden to developing countries, where Zika incidence is high, and these countries are already dealing with increased costs to investigate other causes of microcephaly, such as exposure to chemicals (tobacco and alcohol), radiation and other infectious diseases (HIV, herpes, cytomegalovirus, syphilis, rubella and others). 41 
Guillain-Barr e syndrome
Guillain-Barr e syndrome is a neurological disorder that affects mainly motor axons, resulting from an immune-mediated inflammatory demyelination, usually triggered by an infectious agent. 42 The syndrome is characterized by a fast and progressive ascending limb weakness that, in a few days, can develop into muscular paralysis and a disease resolution that can last for weeks or months. The mortality rate of Guillain-Barr e syndrome is around 5-10%. 43 The annual incidence of Guillain-Barr e syndrome is geographically dependent, with an annual incidence rate of 1Á3 cases per 100 000 individuals, affecting both genders but women have a slightly greater tendency to develop the disorder. 43 Some infectious diseases are known to increase the incidence of Guillain-Barr e syndrome occurrence and Campylobacter jejuni, a bacterium that causes enteritis, has been the pathogen most often implicated with the development of Guillain-Barr e syndrome. Viral infections include Epstein-Barr virus, influenza 44 and, recently, ZIKV infections. The first report of ZIKV associated with the development of Guillain-Barr e syndrome was released in late 2013, during the outbreak in French Polynesia. 45 In 2015, during the Brazilian outbreak, the assumption that ZIKV could lead to the autoimmune Guillain-Barr e syndrome gained more attention after an increase in the syndrome shortly after infection with ZIKV, 46 with an increment of 172% of the disorder by the end of March 2016. A total of 42 cases of Guillain-Barr e syndrome were reported for the French Polynesia ZIKV outbreak 47 and a similar increase has been reported in other Latin American countries that had an occurrence of ZIKV infections, 48 but the immunological or viral factors behind the pathophysiology of this association need to be clarified.
The molecular mechanism in which ZIKV infection can contribute to the development of Guillain-Barr e syndrome is unclear, but it seems to be a little different from Guillain-Barr e syndrome resulting from other infections, such as Campylobacter sp. Cao-Lormeau et al. 49 could not identify a strong antibody response against neuronal glycolipids, such as gangliosides and glycolipid complexes, by conventional antibody detection techniques, such as ELISA and combinatorial microarray analysis. In addition to these results, they could not find a similarity of ZIKV proteins and the glycoprotein GA1 (asialo-GM1 ganglioside), which could generate an autoantibody response to this protein, and hence the Guillain-Barr e syndrome neuro-pathogenesis induced by ZIKV could not be antiglycolipid antibody mediated. More research is needed to understand the mechanism that leads to the development of the disorder after infection by ZIKV infection.
Virus persistence
In addition to all recent discoveries about ZIKV infection, viral persistence is another worrying characteristic of this virus that differentiates it from other flavivirus infections. Viral persistence has been detected in several cases and it might have a correlation with more severe cases of the disease where neuronal involvement may play a role in the development of microcephaly and Guillain-Barr e syndrome. Viral persistence is not common in viruses from the Flavivirus genus, although it is an important feature of hepatitis C virus, a Hepacivirus from the Flaviviridae family. 50 Viral persistence, detected in serum and genital fluids, such as semen 51, 52 and cervical mucus, 53 might be associated with ZIKV sexual and vertical transmission, and persistent aggression to the fetal central nervous system could result in microcephaly. Virus persistence has been detected in ZIKV-infected mice 28 days after infection, where viral RNA was detected in several tissues, such as eyes, brain, tears, lacrimal glands, spleen and other organs, in the absence of virus detection in blood fluids. The importance of RNA detection in these tissues and fluids to infection, specifically in eyes and tears, is clearly indicated as viral particles present in these fluids were proved to be able to infect other animals and replicate after inoculation. 54 The mechanisms on how the virus escapes immune system clearance are not clear, as well as how long the shedding lasts, and whether or not ZIKV remains in a latent stage in some tissues and finally, if viral persistence is associated with more severe outcomes of ZIKV infection.
The association of ZIKV infections and microcephaly urged several health organizations, including the World Health Organization, to publish guidelines regarding the prevention of ZIKV sexual transmission to pregnant women; all of them recommending against unprotected sexual intercourse for 6 months after the diagnosis of ZIKV infection. 55 The importance of ZIKV infections in every period of pregnancy must be determined to define the degree of central nervous impairment. Long-term follow up of in utero-infected children is necessary to diagnose the subtle involvement of the central nervous system.
Immunological response against ZIKV
In the past 2 years, due to the large outbreak of ZIKV in the Americas, there has been a huge contribution from all fields to understand the effects of this infection, and the host response upon ZIKV infection had some important findings. Innate immunity is the first response activated after a viral infection and culminates in interferon and cytokine expression to contain the infection. 56 Different signalling responses are involved in ZIKV infection, but more studies are needed to clarify the completeness of the innate antiviral response. However, as in most flavivirus infections, interferons seem to play a big role in the innate immunity against ZIKV infection. Knockout mice, lacking interferon receptors (ifnar1
) have been extensively used as animal models for ZIKV infection, and it has been demonstrated that the virus can antagonize the interferon response.
Studies of adaptive immunity, which is mediated by B and T lymphocytes and established a few days post-infection, show that ZIKV activates a more pro-inflammatory response, especially through an increased immune response by T C8 + cells. 59 On the other hand, the number of these cytotoxic cells was down-regulated in pregnant mice, a fact that could contribute to intrauterine infection of the fetus. 60 Nevertheless, the antibody response produced after a ZIKV infection still needs extensive studies because a lot of controversial results have ben published, especially due to the cross-reactivity with other flaviviruses that could generate either enhancement or protective effect, both in vitro and in vivo. 61 Recently, it was demonstrated that a previous dengue virus infection does not support the antibody-dependent enhancement of a subsequent ZIKV infection, and the same could be true for expression of inflammatory mediators. 62 If there were no evidence of antibody-dependent enhancement between Zika and dengue viruses, would a previous infection lead to cross-protection and fully neutralize the heterologous virus? Although more studies are needed to elucidate this, some recent data have shown that some specific antibodies produced against dengue virus can protect against ZIKV infection and beyond this, protect against fetal neurological damage. 63 The experiments were performed in vitro and with animal models, but the results are promising and could be a therapeutic tool against ZIKV infection.
Conclusions and future perspectives
Although an incredible amount of knowledge has been produced by research on ZIKV infections, Table 1 highlights a series of research questions that still need to be clarified. In summary, according to all data discussed here, it is crucial to highlight the importance of a more accurate diagnosis of ZIKV infections, especially using serological tests, to differentiate it from other flavivirus infections. This should be a distinctive diagnostic test that could be performed by the public health system of any developing country, presenting accurate results that do not cross-react with other arbovirus infections is a research priority of any country where flavivirus infections are prevalent. A specific diagnostic test that could be applied to a large number of samples could allow for the investigation of the real extent of the outbreak that has occurred in recent years. In addition, the effective diagnosis of ZIKV infection may contribute to the understanding of co-morbidities associated with the severe presentations of ZIKV disease and the mechanisms related to immunological responses against ZIKV. Although the number of suspected ZIKV cases decreased in 2017, the risk of another serious outbreak in Brazil and other tropical and subtropical countries is still prominent. The factors that contributed to the fast spread of ZIKV in previous outbreaks of the disease, such as suitable climate, highly susceptible population and a wide infestation of Aedes mosquitoes, together with widespread circulation of individuals around the globe, can establish ZIKV infection in other countries and trigger future outbreaks. Besides vector control, the development of a safe vaccine candidate is of central importance for ZIKV infection containment, especially for immunocompromised individuals and pregnant women. There is much speculation about the safety of a ZIKV vaccine, and although some candidates are being developed and tested, they should be tested wisely and carefully investigated in terms of the adverse effects these vaccines can cause, in particular the development of Guillain-Barr e syndrome, and the enhancement of other flavivirus diseases by antibodies produced against ZIKV, especially towards a future dengue virus infection. Furthermore, undefined viral tropism and reversal of attenuated viruses make the development of an effective attenuated ZIKV vaccine candidate a big challenge. Finally, due to the possible deleterious effect of an attenuated vaccine on pregnant women, a ZIKV vaccine should be developed keeping in mind that there should be at least two types of vaccines, one to be used in children and another to be administered to women of childbearing age or even during pregnancy.
